Attachment: **No**

Case/Application number: **10595734** PALM
Priority App. Filing Date:
Format for Search Results: **SCORE**

Meaning of unusual acronyms or initialisms:

Identify the novelty:

Additional Comments:
Search compounds of formula (II) in claims 37-39 as filed on 12-20-2010.

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:49:48 ON 26 JAN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Jan 2011  VOL 154 ISS 5
FILE LAST UPDATED: 25 Jan 2011  (20110125/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d stat que l8
L3              STR
```



VAR G1=CH/21
REP G2=(2-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L5 275 SEA FILE=REGISTRY SSS FUL L3
L6 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 1
GGCAT IS MCY AT 2
GGCAT IS MCY AT 4
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L7 21 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
L8 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

=> d ibib abs hitstr l8 1-5

L8 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:663712 HCAPLUS Full-text
DOCUMENT NUMBER: 151:198369

TITLE: Discovery of selective PDE4B inhibitors
AUTHOR(S): Naganuma, Kenji; Omura, Akifumi; Maekawara, Naomi; Saitoh, Masahiro; Ohkawa, Naoto; Kubota, Takashi; Nagumo, Hiromitsu; Kodama, Toshiyuki; Takemura, Masayoshi; Ohtsuka, Yuji; Nakamura, Junji; Tsujita, Ryuichi; Kawasaki, Koh; Yokoi, Hirotsugu; Kawanishi, Masashi
CORPORATE SOURCE: Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni-shi, Shizuoka, 410-2321, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(12), 3174-3176
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 151:198369
GI



I

AB In this study the first PDE4B selective inhibitor is described. Optimization of lead 2-arylpyrimidine derivs. afforded a series of potent PDE4B inhibitors I (R1 = Me, Et, H2C:CHCH2, CN, CHO, etc.; R2 = Me, Et, n-Pr; R3 = Ph, 4-MeC6H4, 2-thienyl, 2-pyridyl, etc.; R4 = H, F; R5 = CO2H, CH2CO2H) with >100-fold selectivity over the PDE4D isoenzyme. With a good pharmacokinetic profile, a selected compound I (R1 = Et; R2 = Me; R3 = 5-chloro-2-thienyl; R4 = H; R5 = CH2CO2H) exhibited potent anti-inflammatory effects in vivo and showed less emesis compared with Cilomilast.

IT 300837-31-4P 1174196-07-6P 1174196-10-1P
1174196-29-2P 1174196-31-6P 1174196-33-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. evaluation of carboxy-substituted (arylamino)pyridimines as selective PDE4B inhibitors)

RN 300837-31-4 HCAPLUS
CN Benzoic acid, 4-[[6-methyl-2-phenyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1174196-07-6 HCAPLUS

CN Benzoic acid, 4-[(6-methyl-2-phenyl-5-propyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 1174196-10-1 HCAPLUS
CN Benzoic acid, 4-[(5-butyl-6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 1174196-29-2 HCAPLUS
CN Benzoic acid, 4-[[6-methyl-2-(4-methylphenyl)-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1174196-31-6 HCAPLUS
CN Benzoic acid, 4-[[6-methyl-2-(3-methylphenyl)-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1174196-33-8 HCAPLUS
CN Benzoic acid, 4-[[2-(4-methoxyphenyl)-6-methyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:464455 HCAPLUS Full-text
DOCUMENT NUMBER: 146:462282
TITLE: Preparation of 2-aminopyrimidines as casein kinase II (CK2) modulators for the treatment of cancer
INVENTOR(S): Rice, Kenneth D.; Blazey, Charles M.; Epshteyn, Sergey; Ibrahim, Mohamed Abdulkader; Johnson, Henry William Beecroft; Kennedy, Abigail R.; Manalo, Jean-Claire Limun; Peto, Csaba J.
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 68pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007048064	A2	20070426	WO 2006-US41501	20061023
WO 2007048064	A3	20070621		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-729348P P 20051021
OTHER SOURCE(S): CASREACT 146:462282; MARPAT 146:462282
GI



I



II

AB Compound I [wherein Z = (un)substituted Ph, thienyl, 2,3-dihydro-1,4-benzodioxinyl or thiazolyl; R1 = (un)substituted alkyl, alkoxy, alkylthio, etc.; R2 = (un)substituted alkyl, aryl or halo; R3 = H, alkyl or halo, etc.] or pharmaceutically acceptable salts thereof were prepared as casein kinase II (CK2) modulators. For instance, chlorination of 2-[[(2-chlorophenyl)methyl]thio]-6-methylpyrimidin-4-ol with POCl3 followed by condensation of the resultant 4-chloropyrimidine with 5-chloroanthranilic acid gave II as a hydrochloride salt. Representative examples I showed CK2 inhibitory activity. The invented compds. and their pharmaceutical compns. are useful for the treatment of diseases that involve CK2, such as cancer.

IT 17174-14-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidines as casein kinase II (CK2) modulators for treatment of cancer)

RN 17174-14-0 HCAPLUS

CN Benzoic acid, 2-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



L8 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:1025025 HCAPLUS Full-text

DOCUMENT NUMBER: 143:455184

TITLE: Electrospray Mass Spectrometry for the Direct Accurate Mass Measurement of Ligands in Complex With the Retinoid X Receptor α Ligand Binding Domain

AUTHOR(S): Lengqvist, Johan; Alvelius, Gunvor; Joernvall, Hans; Sjoevall, Jan; Perlmann, Thomas; Griffiths, William J.

CORPORATE SOURCE: Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Swed.

SOURCE: Journal of the American Society for Mass Spectrometry (2005), 16(10), 1631-1640
CODEN: JAMSEF; ISSN: 1044-0305

PUBLISHER: Elsevier Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Accurate mass measurements are often used in the structural determination of unknown compds. of low mol. mass (i.e., below .apprx.500 Da). Recently, it has been shown that accurate mass measurements also can be made on small denatured proteins (i.e., M r, .apprx.17,000) to confirm their amino acid composition and identify the presence of isoforms. In the current report, the authors present nondenaturing electrospray (ES) mass spectrometry data on the direct accurate mass measurement of ligands in complex with the retinoid X receptor ligand binding domain (RXR LBD; M r 31,370.92). Average mass errors were below 0.198 Da, 6.3 ppm (standard deviation [SD], 0.146; n = 10) for low-affinity fatty acid agonists analyzed in complex with the RXR LBD. Protein consumption was less than 15 pmol, with fatty acid ligands present at concns. corresponding to their median effective concentration value (low micromolar, determined in transfection assays). Although determination of fatty acid mass was only sufficiently accurate to give nominal mass values, measurements were of sufficient accuracy to assign fatty acid chain length, degree of unsatn., or cyclization. Using 17β-estradiol as a control, the ability to observe specific ligand binding is shown for both high- and low-affinity RXRα agonists. In addition, binding of a novel synthetic receptor agonist XCT0315908 to the RXRα LBD is reported. This compound showed a high degree of complex formation, and the receptor-ligand complex could be mass measured with an average mass error of -0.024 Da, 0.8 ppm (SD, 0.092; n = 9). Thus, specific binding of both nanomolar and micromolar affinity ligands to a nuclear receptor LBD can be directly observed using nondenaturing ES mass spectrometry and accurate mass measurements addnl. can be made on intact complexes in the same experiment This methodol. also is applicable when ligands are present as components of mixts.

IT 300837-31-4, XCT 0315908
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(ESI mass spectrometry for mass measurement of ligands in complex with retinoid X receptor α ligand binding domain)

RN 300837-31-4 HCAPLUS

CN Benzoic acid, 4-[[6-methyl-2-phenyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:451367 HCAPLUS Full-text

DOCUMENT NUMBER: 142:476293

TITLE: Substituted pyrimidine compositions and methods using them for the treatment of NGFI-B-related diseases

INVENTOR(S): Martin, Richard; Mohan, Raju; Ordentlich, Peter

PATENT ASSIGNEE(S): X-Ceptor Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047268	A2	20050526	WO 2004-US37642	20041109
WO 2005047268	A3	20050721		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20070293464	A1	20071220	US 2007-595734	20070522

PRIORITY APPLN. INFO.:
US 2003-519030P P 20031110
WO 2004-US37642 W 20041109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:476293

AB Compns. and methods using substituted pyrimidines are provided. The substituted pyrimidines may be used to treat diseases modulated by NGFI-B family activity.

IT 300837-31-4 312626-15-6 333415-58-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidine derivs. for treatment of NGFI-B-related diseases)

RN 300837-31-4 HCAPLUS
CN Benzoic acid, 4-[[6-methyl-2-phenyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 312626-15-6 HCAPLUS
CN Benzoic acid, 4-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 333415-58-0 HCAPLUS
CN Benzoic acid, 3-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1968:459179 HCAPLUS Full-text
DOCUMENT NUMBER: 69:59179
ORIGINAL REFERENCE NO.: 69:11063a,11066a
TITLE: Substituted heteroaromatic anthranilic acids with antiinflammatory activity
AUTHOR(S): Falch, E.; Weis, J.; Natvig, T.
CORPORATE SOURCE: Res. Div., Pharmacia AS, Copenhagen-Vanloese, Den.
SOURCE: Journal of Medicinal Chemistry (1968), 11(3), 608-11
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Anthranilic acids (I and II) containing heteroaromatic N-substituents were prepared by the reaction of appropriately substituted chloro heterocycles with anthranilic acid in HCl or substituted methylthio heterocycles with anthranilic acid in alkaline solution The reaction of o-BrC6H4CO2H with 5-amino-4-carboxy-2,6-dihydroxypyrimidine gave N-[5-(4-carboxy-2,6-dihydroxypyrimidinyl)]anthranilic acid. The exchange of the o-xylyl moiety in mefenamic acid with heteroaromatic rings significantly lowers the antinflammatory activity.
IT 17173-99-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17173-99-8 HCAPLUS
CN Benzoic acid, 2-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> => d stat que l14
L3 STR



VAR G1=CH/21
REP G2=(2-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L5 275 SEA FILE=REGISTRY SSS FUL L3
L6 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 1
GGCAT IS MCY AT 2
GGCAT IS MCY AT 4
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L7 21 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
L8 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L7
L9 254 SEA FILE=REGISTRY ABB=ON PLU=ON L5 NOT L7
L10 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
L13 14 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND (?MEDIC? OR ?THERAP? OR ?DRUG? OR ?PHARM?)
L14 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 NOT L8

=> d ibib abs hitstr l14 1-12

L14 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:846108 HCAPLUS Full-text
DOCUMENT NUMBER: 151:92845
TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds
INVENTOR(S): Goldfarb, David Scott
PATENT ASSIGNEE(S): University of Rochester, USA
SOURCE: U.S. Pat. Appl. Publ., 57pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 20
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				

PRIORITY APPLN. INFO.:
US 2008-23801P P 20080125
US 2007-16362P P 20071221
US 2008-341615 20081222
WO 2008-US88016 W 20081222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses a method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan-altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay. [This abstract record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 337488-98-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)
RN 337488-98-9 HCAPLUS
CN Phenol, 2-[[6-methyl-2-phenyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



L14 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:846107 HCAPLUS Full-text
DOCUMENT NUMBER: 151:92844
TITLE: Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds
INVENTOR(S): Goldfarb, David Scott
PATENT ASSIGNEE(S): University of Rochester, USA
SOURCE: U.S. Pat. Appl. Publ., 57pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 20
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090163545	A1	20090625	US 2008-341615	20081222
US 20090163545	A1	20090625	US 2008-341615	20081222
AU 2008345225	A1	20090709	AU 2008-345225	20081222
CA 2709784	A1	20090709	CA 2008-2709784	20081222
EP 2219646	A2	20100825	EP 2008-867410	20081222
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS				

PRIORITY APPLN. INFO.: US 2008-23801P P 20080125
US 2007-16362P P 20071221
US 2008-341615 20081222
WO 2008-US88016 W 20081222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses a method for altering the lifespan of a eukaryotic organism. The method comprises the steps of providing a lifespan-altering compound, and administering an effective amount of the compound to a eukaryotic organism, such that the lifespan of the organism is altered. In one embodiment, the compound is identified using the DeaD assay. [This abstract record is one of 20 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 313702-68-0
RL: PAC (Pharmacological activity); BIOL (Biological study)
(method using lifespan-altering compds. for altering lifespan of eukaryotic organisms, and screening for such compds.)

RN 313702-68-0 HCAPLUS
CN Phenol, 4-[[6-methyl-2-phenyl-5-(2-propen-1-yl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



L14 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2009:700784 HCAPLUS Full-text
DOCUMENT NUMBER: 151:115596
TITLE: Generation of Ligand-Based Pharmacophore Model and

	Virtual Screening for Identification of Novel Tubulin Inhibitors with Potent Anticancer Activity
AUTHOR(S):	Chiang, Yi-Kun; Kuo, Ching-Chuan; Wu, Yu-Shan; Chen, Chung-Tong; Coumar, Mohane Selvaraj; Wu, Jian-Sung; Hsieh, Hsing-Pang; Chang, Chi-Yen; Jseng, Huan-Yi; Wu, Ming-Hsine; Leou, Jiun-Shyang; Song, Jen-Shin; Chang, Jang-Yang; Lyu, Ping-Chiang; Chao, Yu-Sheng; Wu, Su-Ying
CORPORATE SOURCE:	Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu, 300, Taiwan
SOURCE:	Journal of Medicinal Chemistry (2009), 52(14), 4221-4233 CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A pharmacophore model, Hypo1, was built on the basis of 21 training-set indole compds. with varying levels of antiproliferative activity. Hypo1 possessed important chemical features required for the inhibitors and demonstrated good predictive ability for biol. activity, with high correlation coeffs. of 0.96 and 0.89 for the training-set and test-set compds., resp. Further utilization of the Hypo1 pharmacophore model to screen chemical database in silico led to the identification of four compds. with antiproliferative activity. Among these four compds., 43 showed potent antiproliferative activity against various cancer cell lines with the strongest inhibition on the proliferation of KB cells (IC50 = 187 nM). Further biol. characterization revealed that one complound effectively inhibited tubulin polymerization and significantly induced cell cycle arrest in G2-M phase. In addition, the compound also showed the in vivo-like anticancer effects. To our knowledge, this compound is the most potent antiproliferative compound with antitubulin activity discovered by computer-aided drug design. The chemical novelty of the compound and its anticancer activities make this compound worthy of further lead optimization.

IT 380473-18-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity)

RN 380473-18-7 HCAPLUS

CN Phenol, 2-[4-[(2,5-dimethylphenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	32	THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:640658 HCAPLUS Full-text
DOCUMENT NUMBER: 149:9754
TITLE: Preparation of 2-hydroxy-1,3-diaminopropane derivatives for the treatment of neurological or vascular disorders
INVENTOR(S): Frederiksen, Mathias; Lueoend, Rainer Martin; McCarthy, Clive; Moebitz, Henrik; Rondeau, Jean-Michel; Roy, Bernard Lucien; Rueeger, Heinrich
PATENT ASSIGNEE(S): Novartis A.-G., Switz.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008062044	A1	20080529	WO 2007-EP62701	20071122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007324490	A1	20080529	AU 2007-324490	20071122
CA 2669839	A1	20080529	CA 2007-2669839	20071122
KR 2009091139	A	20090826	KR 2009-7010477	20071122
EP 2094645	A1	20090902	EP 2007-847275	20071122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2010522691	T	20100708	JP 2009-537643	20071122
IN 2009DN02534	A	20100820	IN 2009-DN2534	20090417
CN 101528670	A	20090909	CN 2007-80040090	20090427
MX 2009005182	A	20090525	MX 2009-5182	20090514
US 20100144741	A1	20100610	US 2009-515521	20090519

PRIORITY APPLN. INFO.: EP 2006-124689 A 20061123
WO 2007-EP62701 W 20071122
OTHER SOURCE(S): CASREACT 149:9754; MARPAT 149:9754
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, (un)substituted cycloalkyl, aryl or heteroaryl; R2 = H, halo, alkyl, alkoxy, alkoxy-alkyl, alkylthio, (un)substituted cycloalkyl, cycloalkyl-alkyl or cycloalkyl-alkoxy; R3 = H; R4 = H, alkyl, halogen-substituted alkyl, alkoxy-alkyl, alkylthioalkyl, alkylaminoalkyl, (un)substituted cycloalkyl, aryl or heteroaryl; R5 = H, alkyl, alkoxyalkyl or halogen-substituted alkyl; R6 = H

or alkyl; or R5 and R6 together with the carbon atom, to which they are attached form (un)substituted cycloalkyl; R7 = alkyl, cycloalkylalkyl or halogen-substituted-alkyl; T1-4 independently = CR8, N, O, S or a bond; R8 = H, halo, alkyl, alkoxy or halogen-substituted alkyl], and their pharmaceutically acceptable salts, are prepd as inhibitors of β-secretase. Thus, e.g., II was prepared by reacting N-[(S)-1-((S)-oxiran-2-yl)-2-[4-[(6-phenylpyrimidin-4- yl)amino]phenyl]ethyl]acetamide (preparation given) with [1-(3-isopropylphenyl)cyclopropyl]amine hydrochloride (preparation given). The invention compds. were evaluated for their inhibitory activity of human BACE, BACE-2, human Cathepsin and cellular release of amyloid peptide 1-40, and showed activity at concentration < 50 μM. E.g., II showed inhibition of BACE-activity with an IC50 value of 23 μM. I should prove useful for the treatment of neurol. or vascular disorders related to β-amyloid generation and/or aggregation.

IT 1029719-46-7P, N-[(1S,2R)-3-[[1-(3-tert-Butylphenyl)cyclopropyl]amino]-2-hydroxy-1-[4-[[2-(2-hydroxyphenyl)-6-methylpyrimidin-4-yl]amino]benzyl]propyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxydiaminopropane derivs. for the treatment of neurol. or vascular disorders)

RN 1029719-46-7 HCAPLUS

CN Acetamide, N-[(1S,2R)-3-[[1-[3-(1,1-dimethylethyl)phenyl]cyclopropyl]amino]-2-hydroxy-1-[[4-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]methyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER:	2007:1023400 HCAPLUS Full-text
DOCUMENT NUMBER:	147:357124
TITLE:	Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
INVENTOR(S):	Hannus, Michael; Martin, Cecilie; Mota, Maria M.; Prudencio, Miguel; Rodrigues, Christina Dias
PATENT ASSIGNEE(S):	Cenix Bioscience G.m.b.H., Germany; Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa
SOURCE:	PCT Int. Appl., 127pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007101710	A1	20070913	WO 2007-EP2110	20070309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1832283	A1	20070912	EP 2006-4854	20060309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CA 2645211	A1	20070913	CA 2007-2645211	20070309
EP 1991215	A1	20081119	EP 2007-723162	20070309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101489542	A	20090722	CN 2007-80008109	20080908
US 20090324580	A1	20091231	US 2008-281438	20081212
PRIORITY APPLN. INFO.:			EP 2006-4854 A	20060309
			US 2006-780567P P	20060309
			WO 2007-EP2110 W	20070309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 147:357124

AB The invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria. Administration of ezetimibe to mice injected with Plasmodium berghei significantly reduced liver infection rate. Small interfering RNAs targeting ScarB1 reduced EEF (Exo-Erythrocytic Form) development in human hepatoma cells infected with Plasmodium berghei sporozoites.

IT 330819-79-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of inhibitors of scavenger receptor class proteins for treatment of infectious diseases)

RN 330819-79-9 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-(4-nitrophenyl)-2-phenyl-5-(2-propen-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:1018595 HCAPLUS Full-text
DOCUMENT NUMBER: 147:357121
TITLE: Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
INVENTOR(S): Hannus, Michael; Martin, Cecilie; Mota, Maria M.; Prudencio, Miguel; Rodrigues, Christina Dias
PATENT ASSIGNEE(S): Cenix Bioscience GmbH, Germany; Instituto De Medicina Molecular
SOURCE: Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1832283	A1	20070912	EP 2006-4854	20060309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CA 2645211	A1	20070913	CA 2007-2645211	20070309
WO 2007101710	A1	20070913	WO 2007-EP2110	20070309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1991215	A1	20081119	EP 2007-723162	20070309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101489542	A	20090722	CN 2007-80008109	20080908
US 20090324580	A1	20091231	US 2008-281438	20081212

PRIORITY APPLN. INFO.:		
EP 2006-4854	A	20060309
US 2006-780567P	P	20060309
WO 2007-EP2110	W	20070309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 147:357121

AB The invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria. Administration of ezetimibe to mice injected with Plasmodium berghei significantly reduced liver infection rate. Small interfering RNAs targeting ScarB1 reduced EEF (Exo-Erythrocytic Form) development in human hepatoma cells infected with Plasmodium berghei sporozoites.

IT 330819-79-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(use of inhibitors of scavenger receptor class proteins for treatment of infectious diseases)

RN 330819-79-9 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(4-nitrophenyl)-2-phenyl-5-(2-propen-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:1159256 HCAPLUS Full-text

DOCUMENT NUMBER: 145:471852

TITLE: Preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists

INVENTOR(S): Caroff, Eva; Fretz, Heinz; Hilpert, Kurt; Houille, Olivier; Hubler, Francis; Meyer, Emmanuel

PATENT ASSIGNEE(S): Actelion Pharmaceuticals Ltd, Switz.

SOURCE: PCT Int. Appl., 381pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006114774	A2	20061102	WO 2006-IB51318	20060427
WO 2006114774	A3	20070208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AR 56992	A1	20071107	AR 2006-101670	20060426
AU 2006241260	A1	20061102	AU 2006-241260	20060427
CA 2604967	A1	20061102	CA 2006-2604967	20060427
EP 1893634	A2	20080305	EP 2006-728064	20060427
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2008539224	T	20081113	JP 2008-508400	20060427

BR 2006008089	A2	20091110	BR 2006-8089		20060427
US 20080194576	A1	20080814	US 2007-912545		20071025
MX 2007013436	A	20080116	MX 2007-13436		20071026
CN 101166756	A	20080423	CN 2006-80014374		20071026
KR 2008004608	A	20080109	KR 2007-7026652		20071116
NO 2007006094	A	20080125	NO 2007-6094		20071127
IN 2007CN05449	A	20080328	IN 2007-CN5449		20071128
PRIORITY APPLN. INFO.:			WO 2005-EP4578	A	20050428
			WO 2005-IB53711	A	20051110
			WO 2006-IB51318	W	20060427

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:471852; MARPAT 145:471852
GI



I



II

AB The invention relates to the preparation of title compds. I [R1 = (un)substituted Ph; W = a bond and R2 = CN, halo/alkoxy/heterocyclyl/cyclo/cycloalkyl/alkyl, hetero/ary/, heterocyclyl, (partially) saturated heterocyclyl; (un)substituted hydroxyalkyl; W = CH2 and R2 = NR7R8, SR9, SO2R10; W = O, S, and R2 = alkoxycarbonyl/carboxy/hydroxy/alkoxy/heterocyclyl/cyclo/ar/heteroaryl/alk yl, hetero/aryl; W = NH and derivs. and R2 = H, dialkylamino/alkoxycarbonyl/hydroxy/alkoxy/cyclo/heterocyclyl/cycloalkyl/a r/diphenyl/heteroaryl/alkyl, aryl, 2-phenylcyclopropyl, COR11, SO2R12, (un)substituted carboxyalkyl; W = CH:CH and R2 = hydroxy/alkoxy/alkyl alkoxycarbonyl, Ph, or CONR13R14; ; or W = C.tplbond.C and R2 = H, hydroxy/alkoxy/alkyl; or W = CO and R2 = alkyl; W = NR3 and NR2R3 = 4-7 membered heterocyclyl; or W = NR3 and NR2R3 = (un)substituted imidazoyl, pyrazolyl, 1,2,3-triazolyl, etc.; R5a, R5b = independently H, Me; R3 = H, alkyl; R7 aryl/alkyl; or NR7R8 = (un)substituted 4-7 membered heterocyclyl; R9 = cycloalkyl, aryl; R10 = cyclo/alkyl, aryl; R11 = alkoxy/alkyl, hetero/aryl, etc.; R12 = alkyl, aryl; R13, R14 = independently alkyl; X = CO and R6 = cyclo/alkyl, alk(ynyl)oxy, aryloxy, aralkoxy, hetero/aryl,aralkyl or NH2 and derivs.; or X = SO2 and R6 = alkyl; Y = a bond and Z = H, aryl substituted by carboxyalkoxy; or Y =

alkoxy/Ph/alkoxyphenyl/alkylene, alkoxyphenylene and Z = H, OH, NH2, CO2H, tetrazolyl, CONH2, COOR17, NHCOR17, NHSO2R17; R17 = alkyl], as P2Y12 receptor antagonists. The invention also relates to the use of pyrimidines I and their stereoisomers, salts, solvent complexes and morphol. forms, in the treatment and/or prevention of peripheral vascular, visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases (no data) or conditions associated with platelet aggregation (no data), particularly thrombosis (no data). Thus, a multi-step synthesis starting from Z-L-Glu(Ot-Bu)-OH (Z = benzyloxycarbonyl) and 1-ethoxycarbonylpiperazine was given for amino acid piperazide II. In a P2Y12 binding assay, II had an IC50 = 117 nM.

IT 913948-85-3P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[(2-phenyl-6-phenylaminopyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913948-86-4P, 4-[(S)-4-tert-Butoxycarbonyl-2-[[[6-[(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)

RN 913948-85-3 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(phenylamino)-4-pyrimidinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913948-86-4 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(4-fluorophenyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, 1,1-dimethylethyl ester, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 913947-77-0P, 4-[(S)-4-Carboxy-2-[[(2-phenyl-6-phenylaminopyrimidin-4-yl)carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester 913947-78-1P 913947-79-2P, 4-[(S)-4-Carboxy-2-[[6-[(4-fluorophenyl)amino]-2-phenylpyrimidin-4-yl]carbonyl]amino]butanoyl]piperazine-1-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-(4-pyrimidinylcarbonyl) amino acid piperazides and their use as P2Y12 receptor antagonists)

RN 913947-77-0 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(phenylamino)-4-pyrimidinyl]carbonyl]amino]-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 913947-78-1 HCAPLUS

CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-δ-oxo-γ-[[[2-phenyl-6-(phenylamino)-4-pyrimidinyl]carbonyl]amino]-, (γS)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 913947-77-0
CMF C29 H32 N6 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 913947-79-2 HCAPLUS
CN 1-Piperazinepentanoic acid, 4-(ethoxycarbonyl)-γ-[[[6-[(4-fluorophenyl)amino]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-δ-oxo-, (γS)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:331897 HCAPLUS Full-text
DOCUMENT NUMBER: 140:350578
TITLE: Small organic compounds for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL
INVENTOR(S): Nieland, Thomas J. F.; Krieger, Monty; Kirchhausen, Tomas

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA; Center for Blood Research, Inc.
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032716	A2	20040422	WO 2003-US31918	20031008
WO 2004032716	A9	20040819		
WO 2004032716	A3	20040930		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501685	A1	20040422	CA 2003-2501685	20031008
AU 2003288925	A1	20040504	AU 2003-288925	20031008
US 20040171073	A1	20040902	US 2003-681746	20031008
EP 1562605	A2	20050817	EP 2003-781314	20031008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515274	T	20060525	JP 2004-543548	20031008

PRIORITY APPLN. INFO.:
US 2002-417083P P 20021008
WO 2003-US31918 W 20031008

AB Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically down-regulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels. These results demonstrate that modulation of SR-BI levels, either directly or indirectly, can be used to modulate levels of cholesterol in the blood. Over 200 small organic compds. are identified that alter the transfer of lipids between HDL and cells mediated by the HDL receptor SR-BI, cellular and selective lipid uptake of HDL cholesteryl ether, and efflux of cellular cholesterol to HDL; several compds. have IC50 values in the micromolar or lower range. They specifically alter SR-BI binding, as they required the expression of active SR-BI receptors and they did not interfere with several clathrin-dependent and independent endocytic pathways, the secretory pathway, nor the actin- or tubulin cytoskeletal networks. Strikingly, inhibition of lipid transfer was accompanied by enhanced HDL binding affinity (reduced dissociation rates).

IT 330819-79-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(small organic compds. for modulation of cholesterol transport via regulation of the scavenger receptor SR-BI for HDL)

RN 330819-79-9 HCAPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(4-nitrophenyl)-2-phenyl-5-(2-propen-1-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:261678 HCAPLUS Full-text

DOCUMENT NUMBER: 138:287691

TITLE: Preparation of 4-aminopyrimidine derivatives as insulin secretion accelerators

INVENTOR(S): Yonetoku, Yasuhiro; Maruyama, Tatsuya; Negoro, Kenji; Moritomo, Hiroyuki; Imanishi, Naoki; Shimada, Itsuro; Moritomo, Ayako; Hamaguchi, Wataru; Misawa, Hana; Yoshida, Shigeru; Ohishi, Takahide

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026661	A1	20030403	WO 2002-JP9350	20020912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002330383	A1	20030407	AU 2002-330383	20020912

PRIORITY APPLN. INFO.:

JP 2001-279671	A	20010914
JP 2002-121012	A	20020423
WO 2002-JP9350	W	20020912

OTHER SOURCE(S): MARPAT 138:287691

GI



I

AB Disclosed are insulin secretion accelerators containing the 4-aminopyrimidine derivs. [I; R11 = A11-D11 (wherein A11 = single bond, lower alkylene, lower alkenylene; D11 = each (un)substituted aryl, cycloalkyl, or aromatic or non-aromatic heterocyclyl); R12 = H, lower alkyl optionally substituted by ≥1 groups selected from aryl, halo, lower alkoxy, and OH; R13 = H, Me, F; R14 = H, lower alkyl optionally substituted by ≥1 halogens; R15 = A15-D15 (wherein A15 = single bond, lower alkylene, lower alkenylene; D15 = H, lower alkoxy, amino optionally substituted by 1 or 2 groups selected from lower alkyl and aryl, each (un)substituted aryl, cycloalkyl, or aromatic or non-aromatic heterocyclyl)] or pharmaceutically acceptable salts thereof as the active ingredients. These compds. are highly effective in promoting insulin secretion, increasing insulin content, and inhibiting blood sugar level from increasing and are usable for treatments for insulin-dependent diabetes, non-insulin-dependent diabetes, insulin-resistant diseases, and obesity. Thus, a mixture of 284 mg 2-(4-bromophenyl)-4-chloro-6-methylpyrimidine, 1 mL 70% aqueous ethylamine solution, 2 mL MeOH was stirred at room temperature for 2 h and at 60° for 3 h, treated again with 1 mL 70% aqueous ethylamine solution, and stirred at 60° for 5 h to give 198 mg N-[2-(4-bromophenyl)-6-methylpyrimidin-4- yl]ethylamine (II). II in vitro promoted the secretion of insulin in mouse spleen β-cells by 159% vs. 122% for Glibenclamide.

IT 504404-59-5, 2-[4-[[2-(2,4-Dimethoxyphenyl)-6-methylpyrimidine-4-yl]amino]phenyl]ethanol
RL: RCT (Reactant); RACT (Reactant or reagent)
(demethylation and bromination by hydrogen bromide in acetic acid; preparation of 4-aminopyrimidine derivs. as insulin secretion accelerators for treating diabetes, insulin-resistant diseases, and obesity)

RN 504404-59-5 HCAPLUS

CN Benzeneethanol, 4-[[2-(2,4-dimethoxyphenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



IT 504404-58-4, 2-[3-[[2-(2-Methoxyphenyl)-6-methylpyrimidine-4-yl]amino]phenyl]-N,N-dimethylacetamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(demethylation with pyridine hydrochloride; preparation of 4-aminopyrimidine derivs. as insulin secretion accelerators for treating diabetes, insulin-resistant diseases, and obesity)

RN 504404-58-4 HCAPLUS
CN Benzeneacetamide, 3-[[2-(2-methoxyphenyl)-6-methyl-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



IT 504404-57-3P, 4-Fluoro-N-[2-[2-(methoxymethyl)phenyl]-6-methylpyrimidine-4-yl]aniline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and demethylation with hydrochloric acid in aqueous propanol; preparation of 4-aminopyrimidine derivs. as insulin secretion accelerators for treating diabetes, insulin-resistant diseases, and obesity)
RN 504404-57-3 HCAPLUS
CN 4-Pyrimidinamine, N-(4-fluorophenyl)-2-[2-(methoxymethyl)phenyl]-6-methyl- (CA INDEX NAME)



IT 378217-44-8P 504399-71-7P 504399-74-0P
504399-75-1P 504399-76-2P 504399-77-3P
504399-79-5P 504399-80-8P 504399-82-0P
504399-83-1P 504399-85-3P 504399-88-6P
504399-90-0P 504399-91-1P 504399-92-2P
504401-66-5P 504401-67-6P 504401-68-7P
504404-14-2P 504404-23-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aminopyrimidine derivs. as insulin secretion accelerators for treating diabetes, insulin-resistant diseases, and obesity)
RN 378217-44-8 HCAPLUS
CN Phenol, 2-[4-[(4-fluorophenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 504399-71-7 HCAPLUS
CN Benzenemethanol, 4-[4-[(4-methoxyphenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 504399-74-0 HCAPLUS
CN 4-Pyrimidinamine, N,2-bis(4-methoxyphenyl)-6-methyl- (CA INDEX NAME)



RN 504399-75-1 HCAPLUS
CN Benzeneacetamide, 3-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]amino]- N,N-dimethyl- (CA INDEX NAME)



RN 504399-76-2 HCAPLUS
CN Benzeneacetic acid, 3-[[2-(2-hydroxyphenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 504399-77-3 HCAPLUS
CN 1,3-Benzenediol, 4-[4-[[4-(2-bromoethyl)phenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 504399-79-5 HCAPLUS
CN 4-Pyrimidinamine, 2-(3-chloro-4-fluorophenyl)-6-ethyl-N-[4-[2-(1-oxido-3-pyridinyl)ethyl]phenyl]- (CA INDEX NAME)



RN 504399-80-8 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-methyl-N-[4-[2-(1-oxido-3-pyridinyl)ethyl]phenyl]- (CA INDEX NAME)



RN 504399-82-0 HCAPLUS
CN 4-Pyrimidinemethanol, 2-(4-bromophenyl)-6-[[4-(2-hydroxyethyl)phenyl]amino]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 504399-81-9
CMF C19 H18 Br N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 504399-83-1 HCAPLUS
CN Benzeneacetic acid, 4-[[2-(4-bromophenyl)-6-ethyl-4-pyrimidinyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



RN 504399-85-3 HCAPLUS
CN Methanesulfonamide, N-[2-[4-[[2-(4-bromophenyl)-6-ethyl-4-pyrimidinyl]amino]phenyl]ethyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 504399-84-2
CMF C21 H23 Br N4 O2 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 504399-88-6 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-[4-[[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]ethyl]- (CA INDEX NAME)



RN 504399-90-0 HCAPLUS
CN 1,2-Ethanediamine, N1-[5-[2-[4-[[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]ethyl]-2-pyridinyl]-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 504399-89-7
CMF C26 H27 Br N6



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 504399-91-1 HCAPLUS
CN Benzamide, 4-[4-methyl-6-[[4-[2-(1-oxido-3-pyridinyl)ethyl]phenyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)



RN 504399-92-2 HCAPLUS
CN Pyridinium, 3-[2-[4-[[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]ethyl]-1-methyl-, iodide (1:1) (CA INDEX NAME)



RN 504401-66-5 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-(4-fluorophenyl)-6-methyl- (CA INDEX NAME)



RN 504401-67-6 HCAPLUS
CN Benzenemethanol, 3-[[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 504401-68-7 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-6-methyl- (CA INDEX NAME)



RN 504404-14-2 HCAPLUS
CN Benzeneethanol, 4-[(6-methyl-2-phenyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 504404-23-3 HCAPLUS
CN Benzaldehyde, 4-[4-(1,3-benzodioxol-5-ylamino)-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



IT 504404-55-1, 4-[4-[(4-Methoxyphenyl)amino]-6-methylpyrimidine-2-yl]benzoic acid methyl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(saponification to free acid; preparation of 4-aminopyrimidine derivs. as insulin secretion accelerators for treating diabetes, insulin-resistant diseases, and obesity)
RN 504404-55-1 HCAPLUS
CN Benzoic acid, 4-[4-[(4-methoxyphenyl)amino]-6-methyl-2-pyrimidinyl]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2002:465821 HCAPLUS Full-text
DOCUMENT NUMBER: 137:47211
TITLE: Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis, their preparation, and the use thereof as, e.g., anticancer agents
INVENTOR(S): Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P. Sanjeeva; Pervin, Azra
PATENT ASSIGNEE(S): Cytovia, Inc., USA
SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047690	A1	20020620	WO 2001-US47498	20011212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028922	A	20020624	AU 2002-28922	20011212
US 20030069239	A1	20030410	US 2001-12444	20011212
US 6716851	B2	20040406		
EP 1351691	A1	20031015	EP 2001-990048	20011212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040097503	A1	20040520	US 2003-704448	20031110
US 7226927	B2	20070605		

PRIORITY APPLN. INFO.: US 2000-254581P P 20001212
US 2001-12444 A3 20011212
WO 2001-US47498 W 20011212
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:47211
GI



I



II

AB The invention is directed to substituted 2-aryl-4-(arylamino)pyrimidines I and analogs thereof [Ar1, Ar2 = (independently) optionally substituted aryl or heteroaryl; A = N or C-R2; R1, R2 = (independently) H, halo, haloalkyl, aryl, fused aryl, carbocyclic, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, nitro, amino, cyano, acylamido, OH, SH, acyloxy, N3, alkoxy, aryloxy, arylalkoxy, haloalkoxy, CO2H, carbonylamido, or alkylthio; and R3 = H, optionally substituted alkyl or cycloalkyl]. The invention also relates to the discovery that compds. I are activators of caspases and inducers of apoptosis. I may be used to induce cell death in a variety of clin. conditions in which uncontrolled growth and spread of abnormal cells occurs. In particular, a method of treating disorders responsive to the induction of apoptosis, comprising administration of I, or a pharmaceutically acceptable salt or prodrug thereof, is claimed. Over 200 specific examples of I are described. For instance, condensation of 4-chloro-6-methyl-2-(2-pyridinyl)pyrimidine with 2-chloro-5-methoxyaniline gave title compound II in 44% yield. This compound induced apoptosis and activated caspase cascade in human breast cancer cell lines T-47D and ZR-75-1. Another compound I also showed marked selectivity for human breast cancer cells over other, non-breast cancer cell lines.

IT 300359-08-4P, 4-(4-Methoxyanilino)-6-methyl-2-phenylpyrimidine
438247-48-4P, 4-(4-Methoxyanilino)-6-(methoxymethyl)-2-(3-methylphenyl)pyrimidine 438247-49-5P, 4-(4-Methoxyanilino)-6-methyl-2-(3-methylphenyl)pyrimidine
438247-50-8P, 4-[4-(Dimethylamino)anilino]-6-(methoxymethyl)-2-(3-methylphenyl)pyrimidine 438247-51-9P, 4-[4-(Dimethylamino)anilino]-6-methyl-2-(3-methylphenyl)pyrimidine
438247-54-2P, 4-(3-Methoxyanilino)-6-methyl-2-(3-methylphenyl)pyrimidine 438247-57-5P, 4-(3-Methoxyanilino)-6-(methoxymethyl)-2-(3-methylphenyl)pyrimidine
438247-74-6P, 4-(2,5-Dimethoxyanilino)-6-(methoxymethyl)-2-(3-methylphenyl)pyrimidine 438247-91-7P, 4-(2-Chloro-5-methoxyanilino)-6-(methoxymethyl)-2-(3-methylphenyl)pyrimidine 438247-92-8P, 4-(5-Methoxy-2-methylanilino)-6-(methoxymethyl)-2-(3-methylphenyl)pyrimidine 438248-08-9P, 4-(3-Methoxyanilino)-2-phenyl-6-(trifluoromethyl)pyrimidine
438248-10-3P, 4-(2,5-Dimethoxyanilino)-2-phenyl-6-(trifluoromethyl)pyrimidine 438248-12-5P, 4-(3,4-Dimethoxyanilino)-2-phenyl-6-(trifluoromethyl)pyrimidine
438248-14-7P, 4-(5-Methoxy-2-methylanilino)-2-phenyl-6-(trifluoromethyl)pyrimidine 438248-16-9P, 4-(2-Chloro-5-methoxyanilino)-2-phenyl-6-(trifluoromethyl)pyrimidine
438248-18-1P, 4-(3,4-Methylenedioxyanilino)-2-phenyl-6-(trifluoromethyl)pyrimidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)

RN 300359-08-4 HCAPLUS
CN 4-Pyrimidinamine, N-(4-methoxyphenyl)-6-methyl-2-phenyl- (CA INDEX NAME)



RN 438247-48-4 HCAPLUS
CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(4-methoxyphenyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438247-49-5 HCAPLUS
CN 4-Pyrimidinamine, N-(4-methoxyphenyl)-6-methyl-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438247-50-8 HCAPLUS
CN 1,4-Benzenediamine, N4-[6-(methoxymethyl)-2-(3-methylphenyl)-4-pyrimidinyl]-N1,N1-dimethyl- (CA INDEX NAME)



RN 438247-51-9 HCAPLUS
CN 1,4-Benzenediamine, N1,N1-dimethyl-N4-[6-methyl-2-(3-methylphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 438247-54-2 HCAPLUS
CN 4-Pyrimidinamine, N-(3-methoxyphenyl)-6-methyl-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438247-57-5 HCAPLUS
CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(3-methoxyphenyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438247-74-6 HCAPLUS
CN 4-Pyrimidinamine, N-(2,5-dimethoxyphenyl)-6-(methoxymethyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438247-91-7 HCAPLUS
CN 4-Pyrimidinamine, N-(2-chloro-5-methoxyphenyl)-6-(methoxymethyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438247-92-8 HCAPLUS
CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methoxy-2-methylphenyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 438248-08-9 HCAPLUS
CN 4-Pyrimidinamine, N-(3-methoxyphenyl)-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 438248-10-3 HCAPLUS
CN 4-Pyrimidinamine, N-(2,5-dimethoxyphenyl)-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 438248-12-5 HCAPLUS
CN 4-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 438248-14-7 HCAPLUS
CN 4-Pyrimidinamine, N-(5-methoxy-2-methylphenyl)-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 438248-16-9 HCAPLUS
CN 4-Pyrimidinamine, N-(2-chloro-5-methoxyphenyl)-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 438248-18-1 HCAPLUS
CN 4-Pyrimidinamine, N-1,3-benzodioxol-5-yl-2-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



IT 300359-07-3, 4-(2-Methylanilino)-2-phenyl-6-methylpyrimidine
331648-44-3, 4-(4-Methoxyanilino)-2-(2-hydroxyphenyl)-6-methylpyrimidine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)
RN 300359-07-3 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-(2-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 331648-44-3 HCAPLUS
CN Phenol, 2-[4-[(4-methoxyphenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1976:17420 HCAPLUS Full-text
DOCUMENT NUMBER: 84:17420
ORIGINAL REFERENCE NO.: 84:2894h,2895a
TITLE: 6-Pyrimidinylacetohydroxamic acids for pharmaceutical uses
INVENTOR(S): Fauran, Claude; Eberle, Jeannine; Bourgery, Guy; Raynaud, Guy; Gouret, Claude
PATENT ASSIGNEE(S): Delalande S. A., Fr.
SOURCE: Ger. Offen., 23 pp. Addn. to Ger. Offen. 2,252,822.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2510026	A1	19750925	DE 1975-2510026	19750307
FR 2264529	A2	19751017	FR 1974-9235	19740319
BE 826017	A4	19750826	BE 1975-153774	19750226
CH 567001	A5	19750930	CH 1975-2649	19750303
US 4013768	A	19770322	US 1975-554532	19750303
GB 1438099	A	19760603	GB 1975-8829	19750304
AU 7578821	A	19760909	AU 1975-78821	19750305
ES 435406	A2	19770301	ES 1975-435406	19750307
ZA 7501560	A	19760225	ZA 1975-1560	19750313
JP 50126681	A	19751004	JP 1975-31269	19750317
SE 7503058	A	19750922	SE 1975-3058	19750318
NL 7503227	A	19750923	NL 1975-3227	19750318
SU 530643	A3	19760930	SU 1975-2115291	19750318
PRIORITY APPLN. INFO.:			FR 1974-9235 A	19740319

GI For diagram(s), see printed CA Issue.

AB Pyrimidineacetohydroxamic acids [I, R = o-, p-H2NCO, p-morpholinocarbonyl, p-piperidinocarbonyl, p-pyrrolidinocarbonyl, R1 = m-, p-ClC6H4, m-FC6H4, m-F3CC6H4, 3,4,5-(MeO)3C6H2, 3,4-(methylenedioxy)phenyl] were obtained in 6-71% yields by amination of a chloropyrimidineacetic acid derivative followed by conversion to the hydroxamic acid with NH2OH. I were useful as analgesics, analeptics, antidepressants, diuretics, hypotensive agents, inflammation and ulcer inhibitors, psychotropics, and vasodilators.

IT 57630-88-3P 57630-89-4P 57630-90-7P
57630-91-8P 57630-92-9P 57630-93-0P
57630-94-1P 57630-95-2P 57630-96-3P
57630-97-4P 57630-98-5P 57630-99-6P
57631-00-2P 57631-01-3P 57631-02-4P
57631-03-5P 57659-74-2P 57659-75-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmaceutical uses of)

RN 57630-88-3 HCAPLUS

CN 4-Pyrimidineacetamide, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(4-chlorophenyl)-N-hydroxy- (CA INDEX NAME)



RN 57630-89-4 HCAPLUS

CN 4-Pyrimidineacetamide, 2-(4-chlorophenyl)-N-hydroxy-6-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]- (CA INDEX NAME)



RN 57630-90-7 HCAPLUS

CN 4-Pyrimidineacetamide, 2-(4-chlorophenyl)-N-hydroxy-6-[[4-(1-piperidinylcarbonyl)phenyl]amino]- (CA INDEX NAME)



RN 57630-91-8 HCAPLUS
CN 4-Pyrimidineacetamide, 2-(3-chlorophenyl)-N-hydroxy-6-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



RN 57630-92-9 HCAPLUS
CN 4-Pyrimidineacetamide, 2-(4-chlorophenyl)-N-hydroxy-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]- (CA INDEX NAME)



RN 57630-93-0 HCAPLUS
CN 4-Pyrimidineacetamide, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(3-fluorophenyl)-N-hydroxy- (CA INDEX NAME)



RN 57630-94-1 HCAPLUS
CN 4-Pyrimidineacetamide, 6-[[2-(aminocarbonyl)phenyl]amino]-N-hydroxy-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 57630-95-2 HCAPLUS
CN 4-Pyrimidineacetamide, 6-[[4-(aminocarbonyl)phenyl]amino]-N-hydroxy-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 57630-96-3 HCAPLUS
CN 4-Pyrimidineacetamide, N-hydroxy-6-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 57630-97-4 HCAPLUS
CN 4-Pyrimidineacetamide, N-hydroxy-6-[[4-(1-piperidinylcarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 57630-98-5 HCAPLUS
CN 4-Pyrimidineacetamide, 6-[[2-(aminocarbonyl)phenyl]amino]-N-hydroxy-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 57630-99-6 HCAPLUS

CN 4-Pyrimidineacetamide, 6-[[4-(aminocarbonyl)phenyl]amino]-N-hydroxy-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 57631-00-2 HCAPLUS

CN 4-Pyrimidineacetamide, N-hydroxy-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 57631-01-3 HCAPLUS

CN 4-Pyrimidineacetamide, N-hydroxy-6-[[4-(1-piperidinylcarbonyl)phenyl]amino]-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 57631-02-4 HCAPLUS

CN 4-Pyrimidineacetamide, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(1,3-benzodioxol-5-yl)-N-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



RN 57631-03-5 HCAPLUS
CN 4-Pyrimidineacetamide, 2-(1,3-benzodioxol-5-yl)-N-hydroxy-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



RN 57659-74-2 HCAPLUS
CN 4-Pyrimidineacetamide, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(3-chlorophenyl)-N-hydroxy- (CA INDEX NAME)



RN 57659-75-3 HCAPLUS
CN 4-Pyrimidineacetamide, N-hydroxy-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 57630-67-8 57630-68-9 57630-69-0
57630-70-3 57630-71-4 57630-72-5
57630-73-6 57630-74-7 57630-75-8
57630-76-9 57630-77-0 57630-78-1
57630-79-2 57630-80-5 57630-81-6
57630-82-7 57630-83-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with hydroxylamine)

RN 57630-67-8 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(aminocarbonyl)phenyl]amino]-2-(4-chlorophenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-68-9 HCAPLUS
CN 4-Pyrimidineacetic acid, 2-(4-chlorophenyl)-6-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 57630-69-0 HCAPLUS
CN 4-Pyrimidineacetic acid, 2-(4-chlorophenyl)-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 57630-70-3 HCAPLUS
CN 4-Pyrimidineacetic acid, 2-(4-chlorophenyl)-6-[[4-(1-piperidinylcarbonyl)phenyl]amino]-, ethyl ester (CA INDEX NAME)



RN 57630-71-4 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(3-chlorophenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-72-5 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(3-fluorophenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-73-6 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[2-(aminocarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 57630-74-7 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(aminocarbonyl)phenyl]amino]-2-[3-

(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 57630-75-8 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(1-pyrrolidinylcarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 57630-76-9 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 57630-77-0 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(1-piperidinylcarbonyl)phenyl]amino]-2-[3-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)



RN 57630-78-1 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-79-2 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(aminocarbonyl)phenyl]amino]-2-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-80-5 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-2-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-81-6 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[4-(1-piperidinylcarbonyl)phenyl]amino]-2-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)



RN 57630-82-7 HCAPLUS
CN 4-Pyrimidineacetic acid, 6-[[2-(aminocarbonyl)phenyl]amino]-2-(1,3-benzodioxol-5-yl)-, ethyl ester (CA INDEX NAME)



RN 57630-83-8 HCAPLUS
CN 4-Pyrimidineacetic acid, 2-(1,3-benzodioxol-5-yl)-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L14 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1975:443373 HCAPLUS Full-text
DOCUMENT NUMBER: 83:43373
ORIGINAL REFERENCE NO.: 83:6871a,6874a
TITLE: (Phenylamino)pyrimidine pharmaceuticals
INVENTOR(S): Fauran, Claude; Bourgery, Guy; Raynaud, Guy; Gouret, Claude
PATENT ASSIGNEE(S): Delalande S. A., Fr.
SOURCE: Ger. Offen., 49 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2444426	A1	19750327	DE 1974-2444426	19740917
FR 2244459	A1	19750418	FR 1973-33831	19730920
FR 2265386	A2	19751024	FR 1974-10327	19740326
FR 2265386	B2	19780929		
BE 819057	A1	19750221	BE 1974-147794	19740821
CH 593266	A5	19771130	CH 1974-11401	19740821
GB 1430729	A	19760407	GB 1974-37550	19740828
US 3978055	A	19760831	US 1974-502285	19740903
ZA 7405741	A	19751029	ZA 1974-5741	19740910
JP 50088079	A	19750715	JP 1974-105900	19740913
AU 7473441	A	19760325	AU 1974-73441	19740918

CA 1008074	A1	19770405	CA 1974-209631		19740918
SE 7411806	A	19750321	SE 1974-11806		19740919
SE 410600	B	19791022			
NL 7412494	A	19750324	NL 1974-12494		19740920
US 4025514	A	19770524	US 1976-714472		19760816
US 4041030	A	19770809	US 1976-714473		19760816
SU 698531	A3	19791115	SU 1977-2558803		19771228
PRIORITY APPLN. INFO.:			FR 1973-33831	A	19730920
			FR 1974-10327	A	19740326
			US 1974-502285	A2	19740903
			FR 1976-20775	A	19760707

GI For diagram(s), see printed CA Issue.

AB Pyrimidines I (R = Ph, 4-ClC6H4, 3-FC6H4, 3-F3CC6H4, 3,4-methylenedioxyphenyl, 3,4,5-(MeO)3C6H2; R1 = 4-CONH2, 4-substituted carbamoyl, 2-carboxylic ester, 2-CONH2, 4-CO2Et, 4-aminoethoxy) (77 compds.) were prepared Thus, I [R = 3,4,5-(MeO)3C6H2, R1 = 4-pyrrolidinylcarbonyl] was obtained by treating the 4-chloropyrimidine with 4-pyrrolidinocarbonylaniline. Various I demonstrated sedative, antihypotesive, antiulcer, vasodilator, bronchodilator, diuretic, antihypertensive, pos. inotropic, analgesic, muscle relaxant, and antiinflammatory activities.

IT 56302-92-2P 56303-02-7P 56303-03-8P
56303-05-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic activity of)

RN 56302-92-2 HCAPLUS

CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-phenyl- (CA INDEX NAME)



RN 56303-02-7 HCAPLUS

CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-2-(3-fluorophenyl)-6-methyl- (CA INDEX NAME)



RN 56303-03-8 HCAPLUS

CN 4-Pyrimidinamine, 2-(3-chlorophenyl)-N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl- (CA INDEX NAME)



RN 56303-05-0 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



IT 56302-54-6P 56302-55-7P 56302-64-8P
56303-01-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)

RN 56302-54-6 HCAPLUS
CN Benzoic acid, 4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 56302-55-7 HCAPLUS
CN Benzoic acid, 2-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 56302-64-8 HCAPLUS
CN Benzoic acid, 2-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 56303-01-6 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 56302-75-1P 56302-76-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)
RN 56302-75-1 HCAPLUS
CN Methanone, [4-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 56302-76-2 HCAPLUS
CN Methanone, [4-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]phenyl]-1-piperidinyl- (CA INDEX NAME)



IT 56302-61-5P 56302-74-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and diuretic activity of)
RN 56302-61-5 HCAPLUS

CN Benzamide, 2-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-74-0 HCAPLUS
CN Methanone, [4-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



IT 56302-44-4P 56302-45-5P 56302-46-6P
56302-47-7P 56302-49-9P 56302-51-3P
56302-52-4P 56302-53-5P 56302-59-1P
56302-62-6P 56302-66-0P 56302-67-1P
56302-71-7P 56302-72-8P 56302-77-3P
56302-78-4P 56302-79-5P 56302-81-9P
56302-82-0P 56302-83-1P 56302-84-2P
56302-85-3P 56302-86-4P 56302-87-5P
56302-88-6P 56302-91-1P 56302-93-3P
56302-94-4P 56302-96-6P 56302-97-7P
56302-99-9P 56303-06-1P 56303-07-2P
56303-08-3P 56328-01-9P 56328-03-1P
56328-04-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacological activity of)
RN 56302-44-4 HCAPLUS
CN Benzoic acid, 2-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)



RN 56302-45-5 HCAPLUS
CN Benzoic acid, 2-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-

pyrimidinyl]amino]-, 2,3-dihydroxypropyl ester (CA INDEX NAME)



RN 56302-46-6 HCAPLUS
CN Benzamide, 4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 56302-47-7 HCAPLUS
CN Methanone, [4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 56302-49-9 HCAPLUS
CN Methanone, [4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]-1-piperidinyl- (CA INDEX NAME)



RN 56302-51-3 HCAPLUS
CN Methanone, [4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl](4-phenyl-1-piperazinyl)- (CA INDEX NAME)



RN 56302-52-4 HCAPLUS
CN Benzamide, 2-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-53-5 HCAPLUS
CN Benzamide, 4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-59-1 HCAPLUS
CN Methanone, [4-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 56302-62-6 HCAPLUS
CN Benzamide, 4-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-66-0 HCAPLUS
CN Benzoic acid, 2-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]-, 2,3-dihydroxypropyl ester (CA INDEX NAME)



RN 56302-67-1 HCAPLUS
CN Benzeneacetic acid, 4-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-71-7 HCAPLUS
CN Benzamide, 2-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-72-8 HCAPLUS
CN Benzamide, 4-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-77-3 HCAPLUS
CN Benzamide, 2-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-78-4 HCAPLUS
CN Benzamide, 4-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-79-5 HCAPLUS
CN Benzoic acid, 4-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 56302-81-9 HCAPLUS
CN Benzoic acid, 2-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)



RN 56302-82-0 HCAPLUS

CN Benzoic acid, 2-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]-, 2,3-dihydroxypropyl ester (CA INDEX NAME)



RN 56302-83-1 HCAPLUS
CN Methanone, [4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 56302-84-2 HCAPLUS
CN Methanone, [4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-piperidinyl- (CA INDEX NAME)



RN 56302-85-3 HCAPLUS
CN Methanone, (4-methyl-1-piperazinyl)[4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 56302-86-4 HCAPLUS
CN Methanone, [4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]phenyl](4-phenyl-1-piperazinyl)- (CA INDEX NAME)



RN 56302-87-5 HCAPLUS
CN Benzamide, 2-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-88-6 HCAPLUS
CN Benzamide, 4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 56302-91-1 HCAPLUS
CN Benzoic acid, 2-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)



RN 56302-93-3 HCAPLUS
CN 4-Pyrimidinamine, N-[4-[2-(dipropylamino)ethoxy]phenyl]-6-methyl-2-phenyl-

, hydrochloride (1:1) (CA INDEX NAME)



RN 56302-94-4 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56302-96-6 HCAPLUS
CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 56302-97-7 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (CA INDEX NAME)



RN 56302-99-9 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl- (CA INDEX NAME)



RN 56303-06-1 HCAPLUS
CN 4-Pyrimidinamine, 2-(3-chlorophenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56303-07-2 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 56303-08-3 HCAPLUS
CN 4-Pyrimidinamine, 2-(1,3-benzodioxol-5-yl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56328-01-9 HCAPLUS
CN Methanone, [4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 56328-03-1 HCAPLUS
CN 4-Pyrimidinamine, 2-(3-fluorophenyl)-6-methyl-N-[4-[2-(1-

piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56328-04-2 HCAPLUS
CN 4-Pyrimidinamine, 2-(3-chlorophenyl)-N-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]-6-methyl- (CA INDEX NAME)



IT 56302-43-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with dioxolanemethanol)
RN 56302-43-3 HCAPLUS
CN Benzoic acid, 2-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



IT 56302-63-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and sedative activity of)
RN 56302-63-7 HCAPLUS
CN Benzoic acid, 4-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



IT 56302-65-9P 56302-73-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and vasodilator activity of)
RN 56302-65-9 HCAPLUS
CN Benzoic acid, 2-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)



RN 56302-73-9 HCAPLUS
CN Benzoic acid, 4-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



IT 56302-48-8P 56302-50-2P 56302-56-8P
56302-57-9P 56302-58-0P 56302-60-4P
56302-68-2P 56302-69-3P 56302-70-6P
56302-80-8P 56302-89-7P 56302-90-0P
56302-95-5P 56302-96-6P 56302-98-8P
56303-00-5P 56303-04-9P 56303-09-4P
56303-10-7P 56303-11-8P 56303-12-9P
56303-13-0P 56303-14-1P 56303-15-2P
56328-02-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 56302-48-8 HCAPLUS
CN Methanone, [4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 56302-50-2 HCAPLUS
CN Methanone, [4-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 56302-56-8 HCAPLUS
CN Benzoic acid, 2-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester (CA INDEX NAME)



RN 56302-57-9 HCAPLUS
CN Benzoic acid, 2-[[2-(4-chlorophenyl)-6-methyl-4-pyrimidinyl]amino]-, 2,3-dihydroxypropyl ester (CA INDEX NAME)



RN 56302-58-0 HCAPLUS
CN Methanone, [4-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 56302-60-4 HCAPLUS
CN Methanone, [4-[[2-(3-fluorophenyl)-6-methyl-4-pyrimidinyl]amino]phenyl]-1-piperidinyl- (CA INDEX NAME)



RN 56302-68-2 HCAPLUS
CN Methanone, [4-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 56302-69-3 HCAPLUS
CN Methanone, [4-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 56302-70-6 HCAPLUS
CN Methanone, [4-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl]-1-piperidinyl- (CA INDEX NAME)



RN 56302-80-8 HCAPLUS
CN Benzoic acid, 2-[[2-(1,3-benzodioxol-5-yl)-6-methyl-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 56302-89-7 HCAPLUS
CN Benzoic acid, 4-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 56302-90-0 HCAPLUS
CN Benzoic acid, 2-[[6-methyl-2-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



RN 56302-95-5 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-[4-[2-(1-piperidinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56302-96-6 HCAPLUS
CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 56302-98-8 HCAPLUS
CN 4-Pyrimidinamine, N-[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]-6-methyl-2-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 56303-00-5 HCAPLUS
CN 4-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methyl-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 56303-04-9 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 56303-09-4 HCAPLUS
CN 4-Pyrimidinamine, 2-(3-fluorophenyl)-6-methyl-N-[4-[2-(4-

morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56303-10-7 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-methoxyphenyl)-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56303-11-8 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56303-12-9 HCAPLUS
CN 4-Pyrimidinamine, 2-[4-(dimethylamino)phenyl]-6-methyl-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 56303-13-0 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[2-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (CA INDEX NAME)



RN 56303-14-1 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2-phenyl- (CA INDEX NAME)



RN 56303-15-2 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-[4-[3-(4-morpholinyl)propoxy]phenyl]-2-phenyl- (CA INDEX NAME)



RN 56328-02-0 HCAPLUS
CN Methanone, [4-[[6-methyl-2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]phenyl](4-phenyl-1-piperazinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

```
=> d his nofile

     FILE 'REGISTRY' ENTERED AT 15:45:27 ON 26 JAN 2011
L3             STR
L5          275 SEA SSS FUL L3
L6             STR
L7           21 SEA SUB=L5 SSS FUL L6

     FILE 'HCAPLUS' ENTERED AT 15:49:48 ON 26 JAN 2011
L8            5 SEA ABB=ON  PLU=ON  L7
                D STAT QUE L8
                D IBIB ABS HITSTR L8 1-5

     FILE 'REGISTRY' ENTERED AT 15:50:24 ON 26 JAN 2011
L9          254 SEA ABB=ON  PLU=ON  L5 NOT L7

     FILE 'HCAPLUS' ENTERED AT 15:50:28 ON 26 JAN 2011
L10          22 SEA ABB=ON  PLU=ON  L9
L13          14 SEA ABB=ON  PLU=ON  L10 AND (?MEDIC? OR ?THERAP? OR ?DRUG? OR
                ?PHARM?)
L14          12 SEA ABB=ON  PLU=ON  L13 NOT L8
                D STAT QUE L14
                D IBIB ABS HITSTR L14 1-12

=>
```